<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01719692</url>
  </required_header>
  <id_info>
    <org_study_id>low dose rituximab for ITP</org_study_id>
    <nct_id>NCT01719692</nct_id>
  </id_info>
  <brief_title>Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia</brief_title>
  <acronym>ITP</acronym>
  <official_title>Prospective Multi-center Randomized Controlled Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparative study with rituximab (100 mg weekly for 4 weeks and 375mg/m2 for once) shows
      low dose rituximab may be a useful alternative therapy in patients with ITP.The aim of this
      study is to compare the efficacy and tolerability of two different regimens of low doses
      rituximab for the treatment of adult patients with ITP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hundreds of Patients without infection (age 18 to 60 years old) developed Chronic ITP. All
      patients will be enrolled in this study and will be randomly assigned to receive 100 mg
      rituximab weekly for 4 weeks (group A) or a single dose of 375 mg/m2 rituximab (group B).
      After treatment all patients will be followed for two years. During observation platelet
      count and B lymphocyte will be detected every month.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the platelet count between two groups given different doses of Rituximab.</measure>
    <time_frame>Patients will be followed for 6 months after Rituximab treatment.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Immune Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>Rituximab A group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>375mg/m2 for once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab B group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100mg/week for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Rituximab A group</arm_group_label>
    <arm_group_label>Rituximab B group</arm_group_label>
    <other_name>Trade names Rituxan and MabThera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult chronic ITP, age 18 to 60

        Exclusion Criteria:

          -  pregnant woman with ITP; liver disease and kidney disease; allergy to rituximab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>RENCHI YANG, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital of Blood disease</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital of Blood disease</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2012</study_first_submitted>
  <study_first_submitted_qc>October 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2012</study_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Renchi Yang</investigator_full_name>
    <investigator_title>Thrombosis and Hemostasis Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

